XML 49 R83.htm IDEA: XBRL DOCUMENT
v3.20.2

Investments in Associates and Joint Ventures - Summary of Carrying Value (Details) - CAD ($) | 12 Months Ended
--- | ---
Jun. 30, 2020 | Jun. 30, 2019
Disclosure Of Joint Ventures And Associates [Line Items] |  |
Carrying value of investment, beginning balance | $ 118,845,000 | $ 334,442,000
Additions | 1,775,000 | 8,776,000
Dividend income |  | (828,000)
Disposition / reclassification | (15,645,000) | (136,468,000)
Share of net income (loss) | (11,534,000) | (9,573,000)
Impairment | (75,035,000) | (88,932,000)
Impairment reversal |  | 15,643,000
OCI FX gain (loss) | (292,000) | (4,215,000)
Carrying value of investment, ending balance | 18,114,000 | 118,845,000
Cann Group |  |
Disclosure Of Joint Ventures And Associates [Line Items] |  |
Carrying value of investment, beginning balance | 57,017,000 | 81,183,000
Additions | 0 | 0
Dividend income |  | 0
Disposition / reclassification | 0 | 0
Share of net income (loss) | (2,930,000) | (1,520,000)
Impairment | (37,213,000) | (18,158,000)
Impairment reversal |  | 0
OCI FX gain (loss) | 43,000 | (4,488,000)
Carrying value of investment, ending balance | 16,917,000 | 57,017,000
Alcanna |  |
Disclosure Of Joint Ventures And Associates [Line Items] |  |
Carrying value of investment, beginning balance | 50,950,000 | 109,577,000
Additions | 0 | 0
Dividend income |  | (828,000)
Disposition / reclassification | (15,645,000) | 0
Share of net income (loss) | (7,174,000) | (5,099,000)
Impairment | (27,748,000) | (68,696,000)
Impairment reversal |  | 15,643,000
OCI FX gain (loss) | (383,000) | 353,000
Carrying value of investment, ending balance | 0 | 50,950,000
CTT |  |
Disclosure Of Joint Ventures And Associates [Line Items] |  |
Carrying value of investment, beginning balance | 1,025,000 | 0
Additions | 0 | 3,413,000
Dividend income |  | 0
Disposition / reclassification | 0 | 0
Share of net income (loss) | (58,000) | (230,000)
Impairment | (633,000) | (2,078,000)
Impairment reversal |  | 0
OCI FX gain (loss) | 47,000 | (80,000)
Carrying value of investment, ending balance | 381,000 | 1,025,000
Capcium |  |
Disclosure Of Joint Ventures And Associates [Line Items] |  |
Carrying value of investment, beginning balance | 9,853,000 | 11,256,000
Additions | 0 | 3,000
Dividend income |  | 0
Disposition / reclassification | 0 | 0
Share of net income (loss) | (840,000) | (1,406,000)
Impairment | (9,013,000) | 0
Impairment reversal |  | 0
OCI FX gain (loss) | 0 | 0
Carrying value of investment, ending balance | 0 | 9,853,000
TGOD |  |
Disclosure Of Joint Ventures And Associates [Line Items] |  |
Carrying value of investment, beginning balance | 0 | 132,292,000
Additions | 0 | 0
Dividend income |  | 0
Disposition / reclassification | 0 | (130,974,000)
Share of net income (loss) | 0 | (1,318,000)
Impairment | 0 | 0
Impairment reversal |  | 0
OCI FX gain (loss) | 0 | 0
Carrying value of investment, ending balance | 0 | 0
Choom |  |
Disclosure Of Joint Ventures And Associates [Line Items] |  |
Carrying value of investment, beginning balance | 0 | 0
Additions | 1,775,000 | 0
Dividend income |  | 0
Disposition / reclassification | 0 | 0
Share of net income (loss) | (532,000) | 0
Impairment | (428,000) | 0
Impairment reversal |  | 0
OCI FX gain (loss) | 1,000 | 0
Carrying value of investment, ending balance | 816,000 | 0
ACI |  |
Disclosure Of Joint Ventures And Associates [Line Items] |  |
Carrying value of investment, beginning balance | 0 | 0
Additions | 0 | 5,360,000
Dividend income |  | 0
Disposition / reclassification | 0 | (5,360,000)
Share of net income (loss) | 0 | 0
Impairment | 0 | 0
Impairment reversal |  | 0
OCI FX gain (loss) | 0 | 0
Carrying value of investment, ending balance | 0 | 0
Other immaterial investments |  |
Disclosure Of Joint Ventures And Associates [Line Items] |  |
Carrying value of investment, beginning balance | 0 | 134,000
Additions | 0 | 0
Dividend income |  | 0
Disposition / reclassification | 0 | (134,000)
Share of net income (loss) | 0 | 0
Impairment | 0 | 0
Impairment reversal |  | 0
OCI FX gain (loss) | 0 | 0
Carrying value of investment, ending balance | $ 0 | $ 0

X
- Definition [Line Items] for Disclosure Of Joint Ventures And Associates [Table] + References No definition available. + Details
Name: | acb_DisclosureOfJointVenturesAndAssociatesLineItems
Namespace Prefix: | acb_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Investments In Subsidiaries, Joint Ventures And Associates, Acquired + References No definition available. + Details
Name: | acb_InvestmentsInSubsidiariesJointVenturesAndAssociatesAcquired
Namespace Prefix: | acb_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Investments In Subsidiaries, Joint Ventures And Associates, Disposed Or Reclassified + References No definition available. + Details
Name: | acb_InvestmentsInSubsidiariesJointVenturesAndAssociatesDispositionOrReclassification
Namespace Prefix: | acb_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Investments In Subsidiaries, Joint Ventures And Associates, Foreign Exchange Gain (Loss) + References No definition available. + Details
Name: | acb_InvestmentsInSubsidiariesJointVenturesAndAssociatesForeignExchangeGainLoss
Namespace Prefix: | acb_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of dividends received. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph B12 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B12_a&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_DividendsReceived
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 36 -IssueDate 2019-01-01 -Paragraph 126 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2019-en-r&anchor=para_126_a&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 36 -IssueDate 2019-01-01 -Paragraph 129 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2019-en-r&anchor=para_129_a&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ImpairmentLossRecognisedInProfitOrLoss
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 10 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_10&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of reversal of impairment loss recognised in profit or loss. [Refer: Reversal of impairment loss; Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 36 -IssueDate 2019-01-01 -Paragraph 126 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2019-en-r&anchor=para_126_b&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 36 -IssueDate 2019-01-01 -Paragraph 129 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2019-en-r&anchor=para_129_b&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 23 -Subparagraph g -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23_g&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Paragraph 28 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_28_e&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective on first application of IFRS 9 -Name IFRS -Number 4 -IssueDate 2019-01-01 -Paragraph 39M -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2019-en-b&anchor=para_39M_b&doctype=Standard -URIDate 2019-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 82 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_82_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=acb_CannGroupLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=acb_AlcannaInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=acb_CTTPharmaceuticalHoldingsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=acb_CapciumInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=acb_GreenOrganicDutchmanHoldingsLtd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=acb_ChoomHoldingsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=acb_AustralisCapitalInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_AggregatedIndividuallyImmaterialAssociatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |